Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic iPS cell-derived cardiomyocyte sheet transplantation for dilated cardiomyopathy
jRCT2053230136Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2024
- Countries
- 1
01
Overview
Open-label, single-arm trial in dilated cardiomyopathy (DCM), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Safety up to 52 weeks after transplantation. Started May 2024; status: active, not recruiting.
02
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on jRCT2053230136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053230136.